Ladenburg maintains Ironwood at buy after Synergy results
Ladenburg Thalmann has maintained its “buy” rating and $16 price target on Ironwood Pharmaceuticals (NASDAQ:IRWD) after Synergy Pharmaceuticals (NASDAQ:SGYP) announced results from the plecanatide...
View ArticleLadenburg ups Ironwood target to $18
Ladenburg Thalmann has raised its price target on “buy-rated” Ironwood Pharmaceuticals (NASDAQ:IRWD) to $18 from $16, saying that until recently three factors had depressed the company’s valuation....
View ArticleAddex announces plans to list in U.S.
Swiss-based Addex Therapeutics (SIX:ADXN) has announced plans to list on a U.S. stock exchange as part of several strategic changes, including a focus on rare diseases with at least two programs in the...
View ArticleLadenburg starts Tetraphase at buy
Ladenburg Thalmann has initiated coverage Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a “buy” rating at price target of $13. The stock closed at $8.42 on Tuesday. Tetraphase’s lead product,...
View Article
More Pages to Explore .....